{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:34:24Z","timestamp":1791362064944,"version":"4.3.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jinf.2023.06.023","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:19:44Z","timestamp":1688728784000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prolonged vs short-term infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"87","author":[{"given":"J.","family":"Laporte-Amargos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ulldemolins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Puig-Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Teb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jinf.2023.06.023_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0224465","article-title":"Bloodstream infections caused by Escherichia coli in onco-haematological patients: risk factors and mortality in an Italian prospective survey","volume":"14","author":"Trecarichi","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.023_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","article-title":"Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies","volume":"73","author":"Satlin","year":"2016","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.023_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02494-19","article-title":"Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa","volume":"64","author":"Gudiol","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2023.06.023_bib4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2023.06.023_bib5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.023_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jinf.2023.06.023_bib9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients?","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2023.06.023_bib10","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijantimicag.2005.09.016","article-title":"Trough serum concentrations of \u03b2-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic\/ pharmacodynamic properties of \u03b2-lactams","volume":"27","author":"Navas","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jinf.2023.06.023_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/QCO.0b013e32835915c2","article-title":"Infusional \u03b2-lactam antibiotics in febrile neutropenia: has the time come?","volume":"25","author":"Abbott","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2023.06.023_bib13","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jinf.2023.06.023_bib14","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jinf.2023.06.023_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jiac.2019.02.014","article-title":"Evaluation of pharmacokinetic\/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia","volume":"25","author":"Weber","year":"2019","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2023.06.023_bib16","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.jinf.2023.06.023_bib17","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/jac\/dkaa275","article-title":"A meropenem pharmacokinetics model in patients with haematological malignancies","volume":"75","author":"Contejean","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jinf.2023.06.023_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00311-17","article-title":"Using population pharmacokinetic modeling and monte carlo simulations to determine whether standard doses of piperacillin in piperacillin-tazobactam regimens are adequate for the management of febrile neutropenia","volume":"61","author":"Sime","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jinf.2023.06.023_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ijantimicag.2017.04.008","article-title":"Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens","volume":"50","author":"Rhodes","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jphs.2014.12.003","article-title":"Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia","volume":"127","author":"Jaruratanasirikul","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2023.06.023_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/phar.1875","article-title":"Clinical outcomes of extended versus intermittent infusion of piperacillin\/tazobactam in critically Ill patients: a prospective clinical trial","volume":"37","author":"Fan","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","article-title":"Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely Ill patients: results of a systematic review and meta-analysis","volume":"46","author":"Rhodes","year":"2017","journal-title":"Clin Care Med"},{"key":"10.1016\/j.jinf.2023.06.023_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijid.2020.06.022","article-title":"Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: a systematic review and meta-analysis","volume":"98","author":"Aboulatta","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2023.06.023_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0201667","article-title":"Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jcpt.13301","article-title":"Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: a subgroup meta-analysis and meta-regression analysis","volume":"46","author":"Wu","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.jinf.2023.06.023_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1345\/aph.1M339","article-title":"Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review","volume":"44","author":"Perrott","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib30","first-page":"94","article-title":"Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics","volume":"78","author":"Abdul-Aziz","year":"2012","journal-title":"Minerva Anestesiol"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.023_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jinf.2023.06.023_bib33","first-page":"1","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2023.06.023_bib34","first-page":"4","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2023.06.023_bib35","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods [Internet]. n\/a(n\/a). Available from: \u3008https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/jrsm.1411\u3009."},{"key":"10.1016\/j.jinf.2023.06.023_bib36","series-title":"R: a language and environment for statistical computing [Internet]","author":"Core Team","year":"2022"},{"issue":"8","key":"10.1016\/j.jinf.2023.06.023_bib37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciy258","article-title":"Extended versus bolus infusion of broad spectrum beta-lactams for febrile neutropenia: an unblinded randomized trial","volume":"67","author":"Ram","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2023.06.023_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155216687151","article-title":"Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia","volume":"24","author":"Wrenn","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.jinf.2023.06.023_bib39","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dku150","article-title":"Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study","volume":"69","author":"Feh\u00e9r","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jinf.2023.06.023_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/IPC.0000000000000600","article-title":"Extended versus intermittent infusions of cefepime for the treatment of febrile neutropenia","volume":"26","author":"Przybylski","year":"2018","journal-title":"Infect Dis Clin Pract"},{"issue":"10","key":"10.1016\/j.jinf.2023.06.023_bib41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/phar.2728","article-title":"Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia","volume":"42","author":"Crawford","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.023_bib42","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2023.06.023_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/345435","article-title":"Epidemiology and risk factors for gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy","volume":"36","author":"Cordonnier","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2023.06.023_bib44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciy783","article-title":"Extended infusion of broad-spectrum \u03b2-lactams in high-risk febrile neutropenic patients","volume":"68","author":"Gudiol","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jinf.2023.06.023_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00045-21","article-title":"Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study)","volume":"65","author":"Albasanz-Puig","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jinf.2023.06.023_bib46","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.023_bib47","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/0002-9343(79)90242-0","article-title":"A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients","volume":"67","author":"Bodey","year":"1979","journal-title":"Am J Med"},{"key":"10.1016\/j.jinf.2023.06.023_bib48","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST) [Internet]. Breakpoint tables for interpretation of MICs and zone diameters v 13.0. 2023. Available from: \u3008https:\/\/www.eucast.org\/\u3009."},{"key":"10.1016\/j.jinf.2023.06.023_bib49","series-title":"M100: performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2023"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445323003687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445323003687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:36:21Z","timestamp":1759008981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445323003687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0163445323003687"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2023.06.023","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged vs short-term infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2023.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}